JP2011515152A - 表面を連続波またはパルス光で照射するための方法および装置 - Google Patents
表面を連続波またはパルス光で照射するための方法および装置 Download PDFInfo
- Publication number
- JP2011515152A JP2011515152A JP2011500878A JP2011500878A JP2011515152A JP 2011515152 A JP2011515152 A JP 2011515152A JP 2011500878 A JP2011500878 A JP 2011500878A JP 2011500878 A JP2011500878 A JP 2011500878A JP 2011515152 A JP2011515152 A JP 2011515152A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- scalp
- light
- region
- irradiated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 226
- 230000001678 irradiating effect Effects 0.000 title claims abstract description 66
- 230000003287 optical effect Effects 0.000 claims abstract description 289
- 230000002123 temporal effect Effects 0.000 claims abstract description 49
- 238000011282 treatment Methods 0.000 claims description 385
- 210000004761 scalp Anatomy 0.000 claims description 330
- 210000004556 brain Anatomy 0.000 claims description 200
- 210000003625 skull Anatomy 0.000 claims description 196
- 210000001519 tissue Anatomy 0.000 claims description 91
- 238000004891 communication Methods 0.000 claims description 86
- 238000001126 phototherapy Methods 0.000 claims description 48
- 230000007246 mechanism Effects 0.000 claims description 45
- 239000013307 optical fiber Substances 0.000 claims description 45
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 41
- 208000014674 injury Diseases 0.000 claims description 39
- 230000009529 traumatic brain injury Effects 0.000 claims description 38
- 230000001965 increasing effect Effects 0.000 claims description 30
- 230000004044 response Effects 0.000 claims description 30
- 230000001902 propagating effect Effects 0.000 claims description 29
- 230000033001 locomotion Effects 0.000 claims description 27
- 230000008733 trauma Effects 0.000 claims description 27
- 210000004958 brain cell Anatomy 0.000 claims description 25
- 210000004209 hair Anatomy 0.000 claims description 25
- 239000000463 material Substances 0.000 claims description 24
- 230000008859 change Effects 0.000 claims description 23
- 238000010438 heat treatment Methods 0.000 claims description 23
- 208000024827 Alzheimer disease Diseases 0.000 claims description 22
- 210000004027 cell Anatomy 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 230000005855 radiation Effects 0.000 claims description 18
- 230000004083 survival effect Effects 0.000 claims description 16
- 238000001816 cooling Methods 0.000 claims description 15
- 238000009826 distribution Methods 0.000 claims description 14
- 239000012528 membrane Substances 0.000 claims description 14
- 230000002829 reductive effect Effects 0.000 claims description 14
- 238000003825 pressing Methods 0.000 claims description 13
- 230000004770 neurodegeneration Effects 0.000 claims description 12
- 230000004907 flux Effects 0.000 claims description 10
- 239000002826 coolant Substances 0.000 claims description 9
- 230000008878 coupling Effects 0.000 claims description 9
- 238000010168 coupling process Methods 0.000 claims description 9
- 238000005859 coupling reaction Methods 0.000 claims description 9
- 230000003915 cell function Effects 0.000 claims description 8
- 239000004020 conductor Substances 0.000 claims description 8
- 210000001951 dura mater Anatomy 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 230000031018 biological processes and functions Effects 0.000 claims description 7
- 239000000356 contaminant Substances 0.000 claims description 7
- 238000005452 bending Methods 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 230000003834 intracellular effect Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 230000008929 regeneration Effects 0.000 claims description 6
- 238000011069 regeneration method Methods 0.000 claims description 6
- 230000000740 bleeding effect Effects 0.000 claims description 5
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 claims description 5
- 229910001634 calcium fluoride Inorganic materials 0.000 claims description 5
- 239000010432 diamond Substances 0.000 claims description 4
- 229910052594 sapphire Inorganic materials 0.000 claims description 4
- 239000010980 sapphire Substances 0.000 claims description 4
- PFNQVRZLDWYSCW-UHFFFAOYSA-N (fluoren-9-ylideneamino) n-naphthalen-1-ylcarbamate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1=NOC(=O)NC1=CC=CC2=CC=CC=C12 PFNQVRZLDWYSCW-UHFFFAOYSA-N 0.000 claims description 3
- 229910003460 diamond Inorganic materials 0.000 claims description 3
- 230000035699 permeability Effects 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 229920000690 Tyvek Polymers 0.000 claims description 2
- 239000004775 Tyvek Substances 0.000 claims description 2
- 230000000149 penetrating effect Effects 0.000 claims description 2
- 230000035899 viability Effects 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 description 129
- 241001465754 Metazoa Species 0.000 description 96
- 230000000694 effects Effects 0.000 description 88
- 241000699670 Mus sp. Species 0.000 description 69
- 238000012360 testing method Methods 0.000 description 64
- 238000002647 laser therapy Methods 0.000 description 63
- 238000012384 transportation and delivery Methods 0.000 description 51
- 238000004458 analytical method Methods 0.000 description 49
- 230000000875 corresponding effect Effects 0.000 description 47
- 108090000765 processed proteins & peptides Proteins 0.000 description 47
- 210000003491 skin Anatomy 0.000 description 41
- 241000283973 Oryctolagus cuniculus Species 0.000 description 40
- 230000006378 damage Effects 0.000 description 39
- 238000002560 therapeutic procedure Methods 0.000 description 37
- 208000032382 Ischaemic stroke Diseases 0.000 description 36
- 230000003542 behavioural effect Effects 0.000 description 34
- 230000006870 function Effects 0.000 description 26
- 238000011830 transgenic mouse model Methods 0.000 description 26
- 241000699660 Mus musculus Species 0.000 description 25
- 239000000523 sample Substances 0.000 description 24
- 230000000926 neurological effect Effects 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 210000003128 head Anatomy 0.000 description 22
- 230000006872 improvement Effects 0.000 description 21
- 239000000835 fiber Substances 0.000 description 20
- 238000007477 logistic regression Methods 0.000 description 19
- 238000005259 measurement Methods 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 238000013532 laser treatment Methods 0.000 description 18
- 210000005013 brain tissue Anatomy 0.000 description 17
- 230000007658 neurological function Effects 0.000 description 17
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 16
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 16
- 230000010102 embolization Effects 0.000 description 16
- 230000001976 improved effect Effects 0.000 description 16
- 229960000187 tissue plasminogen activator Drugs 0.000 description 16
- 208000027418 Wounds and injury Diseases 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 14
- 230000006399 behavior Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000009261 transgenic effect Effects 0.000 description 14
- 230000008901 benefit Effects 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 230000002757 inflammatory effect Effects 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 208000012902 Nervous system disease Diseases 0.000 description 12
- 230000002411 adverse Effects 0.000 description 12
- 230000034994 death Effects 0.000 description 12
- 231100000517 death Toxicity 0.000 description 12
- 238000009196 low level laser therapy Methods 0.000 description 12
- 206010014498 Embolic stroke Diseases 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 11
- 230000007423 decrease Effects 0.000 description 11
- 230000007659 motor function Effects 0.000 description 11
- 230000001936 parietal effect Effects 0.000 description 11
- 238000011084 recovery Methods 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000009286 beneficial effect Effects 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 210000002569 neuron Anatomy 0.000 description 10
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 9
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 9
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 238000005286 illumination Methods 0.000 description 9
- 230000007774 longterm Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 230000001276 controlling effect Effects 0.000 description 8
- 230000007547 defect Effects 0.000 description 8
- 230000000302 ischemic effect Effects 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 230000007971 neurological deficit Effects 0.000 description 8
- 238000011555 rabbit model Methods 0.000 description 8
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 7
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 7
- 238000012347 Morris Water Maze Methods 0.000 description 7
- 208000025966 Neurological disease Diseases 0.000 description 7
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 230000001066 destructive effect Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 208000028867 ischemia Diseases 0.000 description 7
- 230000031700 light absorption Effects 0.000 description 7
- 210000003470 mitochondria Anatomy 0.000 description 7
- 230000000324 neuroprotective effect Effects 0.000 description 7
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 7
- 238000002834 transmittance Methods 0.000 description 7
- 206010010071 Coma Diseases 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 6
- 108010002352 Interleukin-1 Proteins 0.000 description 6
- 241000283984 Rodentia Species 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 230000003941 amyloidogenesis Effects 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000007472 neurodevelopment Effects 0.000 description 6
- 230000000258 photobiological effect Effects 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- 230000000472 traumatic effect Effects 0.000 description 6
- 239000003656 tris buffered saline Substances 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 208000037259 Amyloid Plaque Diseases 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 206010061216 Infarction Diseases 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 230000003920 cognitive function Effects 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 238000012937 correction Methods 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 210000003780 hair follicle Anatomy 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 210000001525 retina Anatomy 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000002537 thrombolytic effect Effects 0.000 description 5
- KKTUQAYCCLMNOA-UHFFFAOYSA-N 2,3-diaminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1N KKTUQAYCCLMNOA-UHFFFAOYSA-N 0.000 description 4
- 230000002407 ATP formation Effects 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 206010019196 Head injury Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000006931 brain damage Effects 0.000 description 4
- 231100000874 brain damage Toxicity 0.000 description 4
- 208000029028 brain injury Diseases 0.000 description 4
- 210000001168 carotid artery common Anatomy 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000001427 coherent effect Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000004980 dosimetry Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002008 hemorrhagic effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 230000037380 skin damage Effects 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 3
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 3
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 102100021257 Beta-secretase 1 Human genes 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 108010036933 Presenilin-1 Proteins 0.000 description 3
- 102100022033 Presenilin-1 Human genes 0.000 description 3
- 108010036908 Presenilin-2 Proteins 0.000 description 3
- 102100022036 Presenilin-2 Human genes 0.000 description 3
- 102000006270 Proton Pumps Human genes 0.000 description 3
- 108010083204 Proton Pumps Proteins 0.000 description 3
- IJYPHMXWKKKHGT-VAWYXSNFSA-N SIS3 free base Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)\C=C\C(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 IJYPHMXWKKKHGT-VAWYXSNFSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000006736 behavioral deficit Effects 0.000 description 3
- 230000001764 biostimulatory effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- XLZOVRYBVCMCGL-BPNVQINPSA-L disodium;4-[(z)-[tert-butyl(oxido)azaniumylidene]methyl]benzene-1,3-disulfonate Chemical compound [Na+].[Na+].CC(C)(C)[N+](\[O-])=C\C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O XLZOVRYBVCMCGL-BPNVQINPSA-L 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 230000017525 heat dissipation Effects 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 210000001700 mitochondrial membrane Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 238000011631 stroke animal model Methods 0.000 description 3
- 230000008093 supporting effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010011985 Decubitus ulcer Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241001269524 Dura Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 206010021113 Hypothermia Diseases 0.000 description 2
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 229920005372 Plexiglas® Polymers 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000009692 acute damage Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 238000009227 behaviour therapy Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 210000005257 cortical tissue Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001739 density measurement Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000013161 embolization procedure Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- 239000011539 homogenization buffer Substances 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000003188 neurobehavioral effect Effects 0.000 description 2
- 230000006576 neuronal survival Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000010627 oxidative phosphorylation Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000000608 photoreceptor cell Anatomy 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000004540 process dynamic Methods 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000035806 respiratory chain Effects 0.000 description 2
- 238000012502 risk assessment Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 210000001032 spinal nerve Anatomy 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 208000023516 stroke disease Diseases 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000003685 thermal hair damage Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- MMMVJDFEFZDIIM-UHFFFAOYSA-N 2-$l^{1}-azanyl-2-methylpropane Chemical compound CC(C)(C)[N] MMMVJDFEFZDIIM-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108010094108 Amyloid Proteins 0.000 description 1
- 102000001049 Amyloid Human genes 0.000 description 1
- 206010058178 Aortic occlusion Diseases 0.000 description 1
- JBRZTFJDHDCESZ-UHFFFAOYSA-N AsGa Chemical compound [As]#[Ga] JBRZTFJDHDCESZ-UHFFFAOYSA-N 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 229910004261 CaF 2 Inorganic materials 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000018652 Closed Head injury Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 206010010254 Concussion Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000019736 Cranial nerve disease Diseases 0.000 description 1
- 238000007027 Dakin phenol oxidation reaction Methods 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 241000447437 Gerreidae Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019013 Haemorrhagic infarction Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101100268553 Homo sapiens APP gene Proteins 0.000 description 1
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 1
- 101000720704 Homo sapiens Neuronal migration protein doublecortin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229920006382 Lustran Polymers 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- 238000000342 Monte Carlo simulation Methods 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100025929 Neuronal migration protein doublecortin Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 102000015499 Presenilins Human genes 0.000 description 1
- 206010053395 Progressive multiple sclerosis Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 208000004717 Ruptured Aneurysm Diseases 0.000 description 1
- 241000452413 Sabra Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 101800001111 Soluble APP-alpha Proteins 0.000 description 1
- 102400000571 Soluble APP-alpha Human genes 0.000 description 1
- 101800000130 Soluble APP-beta Proteins 0.000 description 1
- 102400000576 Soluble APP-beta Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 206010042364 Subdural haemorrhage Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 229920006311 Urethane elastomer Polymers 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000012805 animal sample Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 101150031224 app gene Proteins 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 210000000576 arachnoid Anatomy 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- -1 benzene-1, 3-disulfonate N-oxide Chemical class 0.000 description 1
- 108091007737 beta-secretases Proteins 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000002715 bioenergetic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008276 biophysical mechanism Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000035289 cell-matrix adhesion Effects 0.000 description 1
- 210000003570 cell-matrix junction Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GSOLWAFGMNOBSY-UHFFFAOYSA-N cobalt Chemical compound [Co][Co][Co][Co][Co][Co][Co][Co] GSOLWAFGMNOBSY-UHFFFAOYSA-N 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000007370 cognitive improvement Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000036757 core body temperature Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 201000005937 cranial nerve palsy Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000092 effect on stroke Effects 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000005357 flat glass Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 102000038383 gamma-secretases Human genes 0.000 description 1
- 108091007739 gamma-secretases Proteins 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000001795 light effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 230000003923 mental ability Effects 0.000 description 1
- 230000003924 mental process Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000009526 moderate injury Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000009449 neurobehavioral function Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000037420 neurological improvement Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 238000011859 neuroprotective therapy Methods 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000007470 synaptic degeneration Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 229920002725 thermoplastic elastomer Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000000411 transmission spectrum Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0618—Psychological treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0622—Optical stimulation for exciting neural tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/067—Radiation therapy using light using laser light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N2005/002—Cooling systems
- A61N2005/007—Cooling systems for cooling the patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0626—Monitoring, verifying, controlling systems and methods
- A61N2005/0629—Sequential activation of light sources
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0645—Applicators worn by the patient
- A61N2005/0647—Applicators worn by the patient the applicator adapted to be worn on the head
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Neurosurgery (AREA)
- Developmental Disabilities (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Psychology (AREA)
- Social Psychology (AREA)
- Radiation-Therapy Devices (AREA)
- Exposure And Positioning Against Photoresist Photosensitive Materials (AREA)
- Recrystallisation Techniques (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3766808P | 2008-03-18 | 2008-03-18 | |
| US61/037,668 | 2008-03-18 | ||
| US12/389,294 | 2009-02-19 | ||
| US12/389,294 US10357662B2 (en) | 2009-02-19 | 2009-02-19 | Apparatus and method for irradiating a surface with light |
| PCT/US2009/037121 WO2009117323A2 (en) | 2008-03-18 | 2009-03-13 | Method and apparatus for irradiating a surface with continuous-wave or pulsed light |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011515152A true JP2011515152A (ja) | 2011-05-19 |
| JP2011515152A5 JP2011515152A5 (pt) | 2012-04-26 |
Family
ID=40626804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011500878A Pending JP2011515152A (ja) | 2008-03-18 | 2009-03-13 | 表面を連続波またはパルス光で照射するための方法および装置 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2291224A2 (pt) |
| JP (1) | JP2011515152A (pt) |
| CA (1) | CA2718434A1 (pt) |
| WO (1) | WO2009117323A2 (pt) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110831661A (zh) * | 2017-04-14 | 2020-02-21 | 瑞根莱福公司 | 经皮辐照装置和对于神经退行性疾病处置的应用 |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887260B1 (en) | 1998-11-30 | 2005-05-03 | Light Bioscience, Llc | Method and apparatus for acne treatment |
| US20060212025A1 (en) | 1998-11-30 | 2006-09-21 | Light Bioscience, Llc | Method and apparatus for acne treatment |
| US9192780B2 (en) | 1998-11-30 | 2015-11-24 | L'oreal | Low intensity light therapy for treatment of retinal, macular, and visual pathway disorders |
| US6283956B1 (en) | 1998-11-30 | 2001-09-04 | David H. McDaniels | Reduction, elimination, or stimulation of hair growth |
| US7303578B2 (en) | 2001-11-01 | 2007-12-04 | Photothera, Inc. | Device and method for providing phototherapy to the brain |
| WO2004092335A2 (en) | 2003-04-10 | 2004-10-28 | Light Bioscience, Inc. | Photomodulation methods and devices for regulating cell proliferation and gene expression |
| JP4739202B2 (ja) | 2003-07-31 | 2011-08-03 | ジェントルウェイブス エルエルシー | 熱傷、創傷、および関連皮膚疾患の光力学治療のためのシステムおよび方法 |
| US10695579B2 (en) * | 2006-01-30 | 2020-06-30 | Pthera LLC | Apparatus and method for indicating treatment site locations for phototherapy to the brain |
| EP2310094B1 (en) | 2008-07-14 | 2014-10-22 | Arizona Board Regents For And On Behalf Of Arizona State University | Devices for modulating cellular activity using ultrasound |
| US8945196B2 (en) | 2009-05-01 | 2015-02-03 | Wayne State University | Light therapy treatment |
| US10071261B2 (en) | 2009-05-01 | 2018-09-11 | Wayne State University | Light therapy treatment |
| US20160296764A1 (en) * | 2014-07-01 | 2016-10-13 | Gary John Bellinger | Non-invasive and non-ablative soft tissue laser therapy |
| KR20200014798A (ko) * | 2017-05-31 | 2020-02-11 | 데이진 화-마 가부시키가이샤 | 광치료 장치 |
| CA3082878C (en) | 2017-11-17 | 2024-02-20 | The Research Foundation for State University of New York | A method for treating damaged peripheral nerves using x-ray microbeam irradiation |
| CN108478192B (zh) * | 2018-04-11 | 2021-01-15 | 西安交通大学 | 一种用于估测皮肤组织微血管深度的测量系统 |
| USD949355S1 (en) | 2019-10-15 | 2022-04-19 | JelikaLite, LLC | Head wearable light therapy device |
| CN111790060A (zh) * | 2020-04-15 | 2020-10-20 | 西安蓝极医疗电子科技有限公司 | 基于脉冲半导体激光外照射技术治疗脑部疾病的装置 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070179571A1 (en) * | 2006-01-30 | 2007-08-02 | Luis De Taboada | Light-emitting device and method for providing phototherapy to the brain |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047006A (en) * | 1989-11-06 | 1991-09-10 | Howard Brandston | Personal integrating sphere system |
| AU3314297A (en) * | 1996-09-04 | 1998-03-12 | Esc Medical Systems Ltd. | Device and method for cooling skin during laser treatment |
| US5830208A (en) * | 1997-01-31 | 1998-11-03 | Laserlite, Llc | Peltier cooled apparatus and methods for dermatological treatment |
| US7303578B2 (en) * | 2001-11-01 | 2007-12-04 | Photothera, Inc. | Device and method for providing phototherapy to the brain |
| US7351253B2 (en) * | 2005-06-16 | 2008-04-01 | Codman & Shurtleff, Inc. | Intranasal red light probe for treating Alzheimer's disease |
-
2009
- 2009-03-13 CA CA2718434A patent/CA2718434A1/en not_active Abandoned
- 2009-03-13 JP JP2011500878A patent/JP2011515152A/ja active Pending
- 2009-03-13 EP EP09722350A patent/EP2291224A2/en not_active Withdrawn
- 2009-03-13 WO PCT/US2009/037121 patent/WO2009117323A2/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070179571A1 (en) * | 2006-01-30 | 2007-08-02 | Luis De Taboada | Light-emitting device and method for providing phototherapy to the brain |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110831661A (zh) * | 2017-04-14 | 2020-02-21 | 瑞根莱福公司 | 经皮辐照装置和对于神经退行性疾病处置的应用 |
| JP2020516426A (ja) * | 2017-04-14 | 2020-06-11 | レーゲンライフＲｅｇｅｎｌｉｆｅ | 経皮照射装置および神経変性疾患の治療への応用 |
| JP7213864B2 (ja) | 2017-04-14 | 2023-01-27 | レーゲンライフ | 経皮照射装置および神経変性疾患の治療への応用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2718434A1 (en) | 2009-09-24 |
| WO2009117323A3 (en) | 2009-12-10 |
| EP2291224A2 (en) | 2011-03-09 |
| WO2009117323A2 (en) | 2009-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220193443A1 (en) | Method and Apparatus for Irradiating a Surface with Pulsed Light | |
| JP2011515152A (ja) | 表面を連続波またはパルス光で照射するための方法および装置 | |
| US20220126114A1 (en) | Apparatus and method for irradiating a surface with light | |
| US20200330786A1 (en) | Apparatus and Method for Indicating Treatment Site Locations for Phototherapy to the Brain | |
| JP4224102B2 (ja) | 脳に対する光線療法を提供するための装置及び方法 | |
| JP7252997B2 (ja) | 損傷又は疾患組織の非侵襲的治療のための、多重波長光線療法装置、システム及び方法 | |
| US20220152415A1 (en) | Light-Emitting Device And Method For Providing Phototherapy to The Brain | |
| JP5117404B2 (ja) | 脳に光線療法を施すための着装可能なデバイス | |
| Tao et al. | Near infra-red light treatment of Alzheimer’s disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120309 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120309 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131112 |